Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiorella Meneghetti

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Pharmaceutics|February 25, 2023
Targeting Siderophore-Mediated Iron Uptake in <i>M. abscessus</i>: A New Strategy to Limit the Virulence of Non-Tuberculous MycobacteriaMatteo Mori, Giovanni Stelitano, Giulia Cazzaniga, et al.
Archiv Der Pharmazie|May 6, 2024
A hit expansion of 3-benzamidopyrazine-2-carboxamide: Toward inhibitors of prolyl-tRNA synthetase with antimycobacterial activityVinod Sukanth Kumar Pallabothula, Nechirwan Taimur Abdalrahman, Matteo Mori, et al.
Journal of Medicinal Chemistry|March 3, 2025
Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis TherapyGiulia Cazzaniga, Matteo Mori, Anna Griego, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Pharmaceutics|February 25, 2023
Targeting Siderophore-Mediated Iron Uptake in <i>M. abscessus</i>: A New Strategy to Limit the Virulence of Non-Tuberculous MycobacteriaMatteo Mori, Giovanni Stelitano, Giulia Cazzaniga, et al.
Archiv Der Pharmazie|May 6, 2024
A hit expansion of 3-benzamidopyrazine-2-carboxamide: Toward inhibitors of prolyl-tRNA synthetase with antimycobacterial activityVinod Sukanth Kumar Pallabothula, Nechirwan Taimur Abdalrahman, Matteo Mori, et al.
Journal of Medicinal Chemistry|March 3, 2025
Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis TherapyGiulia Cazzaniga, Matteo Mori, Anna Griego, et al.
Pageof 9